Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mirogabalin

- PMLiVE

GSK throws gauntlet down to Merck with shingles vaccine data

Shingrix trial reported ninety per cent efficacy in elderly patients who do not respond well to Zostavax

- PMLiVE

Daiichi Sankyo promotes Dr Marielle Cohard-Radice

She becomes executive vice president, global head of development

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

Biomarin

BioMarin gives up on muscular dystrophy drug

Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

- PMLiVE

Cell Therapy licenses heart failure therapy in Japan

EMA may grant Welsh-based biotech a marketing application in mid-2016

- PMLiVE

Dr Antoine Yver moves from AstraZeneca to Daiichi Sankyo

He becomes global head, oncology research and development

- PMLiVE

Daiichi Sankyo collaborates on e-patient AF resource

Will work with European platform People Who on new illness profile

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

Daiichi Sankyo logo

Daiichi Sankyo to shut down German antibody unit U3

Will transfer its operations to a research unit in Japan

Daiichi Sankyo logo

Daiichi Sankyo cuts a swathe through US workforce

Plans to shed upto 1,200 jobs across the US

Daiichi Sankyo logo

Daiichi Sankyo licenses clot-busting antibody

New drug TS23 could be more much effective for ischemic stroke

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links